Vanguard Group Inc. boosted its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 4.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 745,237 shares of the specialty pharmaceutical company’s stock after acquiring an additional 28,818 shares during the quarter. Vanguard Group Inc. owned 3.33% of Adamas Pharmaceuticals worth $13,034,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Goldman Sachs Group Inc. lifted its position in Adamas Pharmaceuticals by 212.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock worth $1,066,000 after buying an additional 41,436 shares in the last quarter. Granite Point Capital Management L.P. lifted its position in Adamas Pharmaceuticals by 11.9% during the 2nd quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock worth $4,609,000 after buying an additional 28,000 shares in the last quarter. Alliancebernstein L.P. lifted its position in Adamas Pharmaceuticals by 2.6% during the 2nd quarter. Alliancebernstein L.P. now owns 717,617 shares of the specialty pharmaceutical company’s stock worth $12,551,000 after buying an additional 17,972 shares in the last quarter. Emerald Advisers Inc. PA lifted its position in Adamas Pharmaceuticals by 2.7% during the 2nd quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock worth $9,317,000 after buying an additional 14,042 shares in the last quarter. Finally, State of Wisconsin Investment Board lifted its position in Adamas Pharmaceuticals by 11.0% during the 2nd quarter. State of Wisconsin Investment Board now owns 111,000 shares of the specialty pharmaceutical company’s stock worth $1,941,000 after buying an additional 11,000 shares in the last quarter. 76.24% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/vanguard-group-inc-boosts-position-in-adamas-pharmaceuticals-inc-adms/1717088.html.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) opened at $29.96 on Tuesday. Adamas Pharmaceuticals, Inc. has a 52 week low of $13.50 and a 52 week high of $30.49. The company has a debt-to-equity ratio of 0.41, a quick ratio of 8.32 and a current ratio of 8.35.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.03). The firm’s quarterly revenue was down 99.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.66) EPS. research analysts expect that Adamas Pharmaceuticals, Inc. will post -3.87 earnings per share for the current year.

Several equities research analysts have commented on the stock. Noble Financial boosted their price target on shares of Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Piper Jaffray Companies reissued an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Adamas Pharmaceuticals in a research report on Sunday, September 17th. Finally, Mizuho reissued a “buy” rating and set a $26.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, September 5th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. Adamas Pharmaceuticals presently has an average rating of “Buy” and an average price target of $42.00.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.